{"id":7801,"date":"2026-02-24T06:08:28","date_gmt":"2026-02-24T06:08:28","guid":{"rendered":"https:\/\/pandapeptides.com\/research\/aod-9604\/"},"modified":"2026-04-09T14:26:08","modified_gmt":"2026-04-09T21:26:08","slug":"aod-9604","status":"publish","type":"page","link":"https:\/\/pandapeptides.com\/es\/research\/aod-9604\/","title":{"rendered":"AOD-9604 \u2014 Published Research"},"content":{"rendered":"
\n

\u2190 Back to AOD-9604 product page<\/a><\/p>\n

\n

Biblioteca de investigaci\u00f3n<\/h3>\n

Published research on AOD-9604 \u2014 for educational purposes only<\/p>\n

\nHGH Fragment 177-191 Structure and Mechanism<\/summary>\n
\n

The C-terminal fragment of human GH (residues 177\u2013191) was identified through structure-function studies as a region involved in lipolytic activity. Unlike full-length GH, the fragment does not bind to the GH receptor (GHR), does not stimulate IGF-1 production, and does not induce longitudinal bone growth. Research suggests the fragment may interact with beta-3 adrenergic receptors on adipocytes or act through an as-yet-unidentified receptor distinct from GHR. The lipolytic domain is conformationally distinct from the somatogenic (growth-promoting) domains of GH. Research compound \u2014 not for human use.<\/p>\n

Ng FM et al. “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.” Horm Res.<\/em> 2000. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nAOD-9604 in Adipocyte Lipid Metabolism Models<\/summary>\n
\n

In vitro studies using 3T3-L1 adipocytes demonstrated that AOD-9604 stimulated lipolysis (glycerol release) and inhibited lipogenesis (fatty acid incorporation into triglycerides). The anti-lipogenic effect appears to involve suppression of acetyl-CoA carboxylase and fatty acid synthase enzyme activities. In obese mouse models, chronic AOD-9604 administration did not alter IGF-1 levels or glucose\/insulin homeostasis markers, consistent with its lack of GHR binding. Research compound \u2014 not for human use.<\/p>\n

Heffernan MA et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.” Endocrinology.<\/em> 2001. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nAOD-9604 Preclinical Safety Profile<\/summary>\n
\n

Preclinical safety characterization of AOD-9604 included standard genotoxicity assays (Ames test, chromosomal aberration assay, micronucleus test), all of which showed no mutagenic activity. Chronic administration studies in rodent models monitored hematology, clinical chemistry, and IGF-1 levels to confirm the absence of GH-like somatogenic activity. The safety data support AOD-9604’s classification as a non-GHR-binding peptide fragment. Research compound \u2014 not for human use.<\/p>\n

Stier H et al. “Safety of AOD9604, a Synthetic Peptide Fragment of Human Growth Hormone, in a Comprehensive Safety Assessment.” J Obesity Eating Disord.<\/em> 2019. J Obes Eat Disord<\/a><\/p>\n<\/div>\n<\/details>\n<\/div>\n

\n

Disclaimer:<\/strong> All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u2190 Back to AOD-9604 product page Research Library Published research on AOD-9604 \u2014 for educational purposes only HGH Fragment 177-191 Structure and Mechanism The C-terminal fragment of human GH (residues 177\u2013191) was identified through structure-function studies as a region involved in lipolytic activity. Unlike full-length GH, the fragment does not bind to the GH receptor […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7787,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7801","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/comments?post=7801"}],"version-history":[{"count":2,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7801\/revisions"}],"predecessor-version":[{"id":8632,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7801\/revisions\/8632"}],"up":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7787"}],"wp:attachment":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/media?parent=7801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}